TG Therapeutics vs Travere Therapeutics
TGTX and TVTX side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How TGTX and TVTX compare
TG Therapeutics is the larger company, worth 2.0 times as much as Travere Therapeutics ($9.6B against $4.8B).
Travere Therapeutics grew revenue faster over the last twelve months (77.1% versus 76.1% for TG Therapeutics).
TG Therapeutics keeps more of each dollar of sales as profit, with a net margin of 55.2% compared with −7.4% at Travere Therapeutics.
TG Therapeutics scores higher on the StockData Score (9 against 6 for Travere Therapeutics), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | TGTX | TVTX |
|---|---|---|
| Size and price | ||
| Market cap | $9.6B | $4.8B |
| Share price | $62.71 | $51.10 |
| Change, 1 year | 102% | 48.1% |
| Change, 5 years | 162% | 76.0% |
| Beta (5Y) | 0.47 | 1.91 |
| Employees | 399 | 497 |
| StockData Score | ||
| Total score | 9 (better) | 6 |
| Valuation score | 1 (better) | 0 |
| Growth score | 2 | 3 (better) |
| Performance score | 4 (better) | 2 |
| Health score | 2 (better) | 1 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/E | 22.9× | – |
| P/S | 12.0× | 8.1× (better) |
| P/B | 15.9× (better) | 196× |
| EV/EBITDA | 71.3× (better) | 197× |
| P/FCF | 552× | – |
| FCF yield | 0.18% | – |
| Fair value | $60.66 | $6.01 |
| Margin of safety | −3.4% (better) | −751% |
| Growth | ||
| Revenue growth (TTM) | 76.1% | 77.1% (better) |
| Revenue growth, 5Y average | 427% (better) | 19.9% |
| Net income growth (TTM) | 630% | – |
| EPS growth (TTM) | 641% | – |
| Profitability | ||
| Gross margin | 82.4% | 98.6% (better) |
| Operating margin | 17.1% (better) | −6.8% |
| Net margin | 55.2% (better) | −7.4% |
| FCF margin | 2.2% | – |
| Return on equity | 100% (better) | −152% |
| Return on invested capital | 27.8% | – |
| Financial health | ||
| Debt / equity | 1.23 | – |
| Net debt / EBITDA | 0.98 | – |
| Interest coverage | 3.6× (better) | −4.3× |
| Current ratio | 4.27 (better) | 4.05 |
| Altman Z-score | 6.07 (better) | 2.29 |
| Piotroski F-score | 4 | 7 (better) |
| Dividends and buybacks | ||
| Buyback yield | 1.9% | – |
| Shareholder yield | 1.9% (better) | 0.00% |
| Ownership | ||
| Held by institutions | 72.6% | 112% |
| Held by insiders | 16.1% | 1.6% |
| Insider net buying, 12 months | −$275K (better) | −$110M |
| Short interest, % of float | 22.4% | 10.3% |
Go deeper
- TGTX stock overview
- TGTX income statement
- TGTX valuation and score
- TVTX stock overview
- TVTX income statement
- TVTX valuation and score
Other comparisons
For information only, not investment advice. Check the source filings before relying on any figure.